RxSight, Inc. (RXST)

USD 37.2

(-2.21%)

Market Cap (In USD)

1.49 Billion

Revenue (In USD)

89.07 Million

Net Income (In USD)

-48.6 Million

Avg. Volume

585.35 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
34.92-66.54
PE
-
EPS
-
Beta Value
1.191
ISIN
US78349D1072
CUSIP
78349D107
CIK
1111485
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Ronald M. Kurtz M.D.
Employee Count
-
Website
https://www.rxsight.com
Ipo Date
2021-07-30
Details
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.